38 results on '"Folks, Thomas"'
Search Results
2. Chimpanzees as original source for HIV.
- Author
-
Folks, Thomas M. and Folks, T M
- Subjects
- *
HIV , *VIRUS-induced immunosuppression , *CHIMPANZEES , *DISEASES - Abstract
Offers information on the origin of the HIV-1 virus in the chimpanzee. How viruses related to HIV-1 have been isolated from the common chimpanzee; Determination that the subspecies identity of all known SIVcpz-infected chimpanzees; How P.t. troglodytes is the primary reservoir for HIV-1 and has been the source of at least three independent introductions of SIVcpz into the human population. INSET: Origin of HIV-1 in the Chimpanzee.
- Published
- 2000
- Full Text
- View/download PDF
3. Xenotransplantation and Xenogeneic Infections.
- Author
-
Chapman, Louisa E., Folks, Thomas M., Salomon, Daniel R., Patterson, Amy P., Eggerman, Thomas E., and Noguchi, Philip D.
- Subjects
- *
ZOONOSES , *DISEASE risk factors - Abstract
Reports that the use of xenogenic tissues in transplantation has raised concern about potential infection with both recognized zoonotic pathogens and unknown xenogenic agents. Authorities argument; Transplant recipients risk; Public health potential threat; Minimizing public health risks; References.
- Published
- 1995
- Full Text
- View/download PDF
4. Viral and Immunologic Examination of Human Immunodeficiency Virus Type 1-Infected, Persistently Seronegative Persons.
- Author
-
Ellenberger, Dennis L., Dorn, Jonathan, Folks, Thomas M., Sullivan, Patrick S., Schable, Charles, Spira, Thomas J., and Lal, Renu B.
- Subjects
- *
HIV-positive persons , *IMMUNOLOGY , *HIV , *DISEASES - Abstract
Examines the viral and immunologic complications of HIV-positive patients. Determination of whether persistent seronegativity was attributable to immune dysfunction or infection; Results of the in vitro stimulation of peripheral blood mononuclear cells.
- Published
- 1999
- Full Text
- View/download PDF
5. Cellular aspects of HIV infection: Edited by A. Cossarizza, D. Kaplan, Wiley-Liss, Baffins Lane, Chichester, West Sussex PO19 1UD, UK, 0471386669; £103.00
- Author
-
Folks, Thomas
- Published
- 2002
- Full Text
- View/download PDF
6. Retroviral Immunology. Immune Response and Restoration: G. Pantaleo, B.D. Walker (Eds.); Humana Press, Totowa, NJ 07512, ISBN 0-89603-675-8, US$135.00
- Author
-
Folks, Thomas
- Published
- 2002
- Full Text
- View/download PDF
7. Resource brief: The National Non-Human Primate DNA Bank
- Author
-
Ferguson, Betsy, Capitanio, John, Folks, Thomas, Hotchkiss, Charlotte, Johnson, Zachary, Kean, Leslie, Kubisch, H. Michael, Lank, Simon, Lyons, Leslie, Miller, Gregory M., Nylander, John, O’Connor, David, Vallender, Eric J., and Wiseman, Roger
- Subjects
- *
DNA data banks , *PRIMATE genetics , *GENOMICS , *MACAQUES , *COMPARATIVE studies , *RESEARCH institutes - Abstract
Abstract: A National Non-Human Primate (NHP) DNA bank has been established by the National Primate Research Centers and the National Center for Research Resources, NIH, providing a new resource for comparative genomic studies. The collection includes genomic DNA samples from macaques, chimpanzees, baboons, vervets, marmosets, sooty mangabeys and titi monkeys. The repository includes DNAs from 697 unrelated animals, suitable for comparing allele representation within and between species. Another 474 DNAs are derived from family-trios (dam, sire, off spring), and are useful for verifying the segregation of genetic variants. The National NHP DNA Bank includes specified holdings within each of the eight National Primate Research Centers, though detailed information on the entire collection is available through a common website. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
8. Simian retroviral infections in human beings.
- Author
-
Wolfe, Nathan D., Switzer, William M., Folks, Thomas M., Burke, Donald S., and Heneine, Walid
- Subjects
- *
LETTERS to the editor , *RETROVIRUS diseases - Abstract
Presents a reply to a letter to the editor in regards to an article published in a previous issue which discussed simian retroviral infections in human beings.
- Published
- 2004
- Full Text
- View/download PDF
9. Simian T-Lymphotropic Virus Diversity among Nonhuman Primates, Cameroon.
- Author
-
Sintasath, David M., Wolfe, Nathan D., LeBreton, Matthew, Hongwei Jia, Garcia, Albert D., Diffo, Joseph Le Doux, Tamoufe, Ubald, Carr, Jean K., Folks, Thomas M., Mpoudi-Ngole, Eitel, Burke, Donald S., Heneine, Walid, and Switzer, William M.
- Subjects
- *
RETROVIRUSES , *T cells , *PHYLOGENY , *MONKEYS , *CERCOPITHECUS , *DNA - Abstract
Cross-species transmission of retroviruses is common in Cameroon. To determine risk for simian T-cell lymphotropic virus (STLV) transmission from nonhuman primates to hunters, we examined 170 hunter-collected dried blood spots (DBS) from 12 species for STLV. PCR with generic tax and group-specific long terminal repeat primers showed that 12 (7%) specimens from 4 nonhuman primate species were infected with STLV. Phylogenetic analyses showed broad diversity of STLV, including novel STLV-1 and STLV-3 sequences and a highly divergent STLV-3 subtype found in Cercopithecus mona and C. nictitans monkeys. Screening of peripheral blood mononuclear cell DNA from 63 HTLV-seroreactive, PCR-negative hunters did not identify human infections with this divergent STLV-3. Therefore, hunter-collected DBS can effectively capture STLV diversity at the point where pathogen spillover occurs. Broad screening using this relatively easy collection strategy has potential for large-scale monitoring of retrovirus cross-species transmission among highly exposed human populations. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
10. Ancient, independent evolution and distinct molecular features of the novel human T-lymphotropic virus type 4.
- Author
-
Switzer, William M., Salemi, Marco, Qari, Shoukat H., Hongwei Jia, Gray, Rebecca R., Katzourakis, Aris, Marriott, Susan J., Pryor, Kendle N., Wolfe, Nathan D., Burke, Donald S., Folks, Thomas M., and Heneine, Walid
- Subjects
- *
PUBLIC health research , *LYMPHOCYTES , *GENOMES , *NUCLEOTIDES , *B cells , *INFECTIOUS disease transmission - Abstract
Background: Human T-lymphotropic virus type 4 (HTLV-4) is a new deltaretrovirus recently identified in a primate hunter in Cameroon. Limited sequence analysis previously showed that HTLV-4 may be distinct from HTLV-1, HTLV-2, and HTLV-3, and their simian counterparts, STLV- 1, STLV-2, and STLV-3, respectively. Analysis of full-length genomes can provide basic information on the evolutionary history and replication and pathogenic potential of new viruses. Results: We report here the first complete HTLV-4 sequence obtained by PCR-based genome walking using uncultured peripheral blood lymphocyte DNA from an HTLV-4-infected person. The HTLV-4(1863LE) genome is 8791-bp long and is equidistant from HTLV-1, HTLV-2, and HTLV-3 sharing only 62-71% nucleotide identity. HTLV-4 has a prototypic genomic structure with all enzymatic, regulatory, and structural proteins preserved. Like STLV-2, STLV-3, and HTLV-3, HTLV-4 is missing a third 21-bp transcription element found in the long terminal repeats of HTLV- 1 and HTLV-2 but instead contains unique c-Myb and pre B-cell leukemic transcription factor binding sites. Like HTLV-2, the PDZ motif important for cellular signal transduction and transformation in HTLV-1 and HTLV-3 is missing in the C-terminus of the HTLV-4 Tax protein. A basic leucine zipper (b-ZIP) region located in the antisense strand of HTLV-1 and believed to play a role in viral replication and oncogenesis, was also found in the complementary strand of HTLV- 4. Detailed phylogenetic analysis shows that HTLV-4 is clearly a monophyletic viral group. Dating using a relaxed molecular clock inferred that the most recent common ancestor of HTLV-4 and HTLV-2/STLV-2 occurred 49,800 to 378,000 years ago making this the oldest known PTLV lineage. Interestingly, this period coincides with the emergence of Homo sapiens sapiens during the Middle Pleistocene suggesting that early humans may have been susceptible hosts for the ancestral HTLV- Conclusion: The inferred ancient origin of HTLV-4 coinciding with the appearance of Homo sapiens, the propensity of STLVs to cross-species into humans, the fact that HTLV-1 and -2 spread globally following migrations of ancient populations, all suggest that HTLV-4 may be prevalent. Expanded surveillance and clinical studies are needed to better define the epidemiology and public health importance of HTLV-4 infection. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
11. Coinfection with HIV-1 and Simian Foamy Virus in West Central Africans.
- Author
-
Switzer, William M., Garcia, Albert D., Chunfu Yang, Wright, Anthony, Kalish, Marcia L., Folks, Thomas M., and Heneine, Walid
- Subjects
- *
HIV infections , *HIV , *VIRUSES , *BLOOD plasma , *SEXUALLY transmitted diseases , *INFECTION , *BLOOD donors , *HIV-positive persons - Abstract
Frequent infection with zoonotic simian foamy virus (SFV) has been reported among HIV-negative primate hunters in rural Cameroon. Plasma samples obtained from urban commercial sex workers (CSWs; n= 139), patients with sexually transmitted diseases (n = 41), and blood donors (n= 179) in the Democratic Republic of Congo [formerly known as Zaire] and Cameroon were tested for SFV and HIV-1 infection. One CSW and one blood donor were found to be seropositive for both SFV and HIV-1, thereby documenting what are, to our knowledge, the first reported cases of dual SFV and HIV infection. The findings of the present study suggest opportunities for bloodborne and sexual transmission of SFV and highlight the importance of defining the clinical consequences of dual infections. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
12. Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and Tenofovir.
- Author
-
García-Lerma, J. Gerardo, Otten, Ron A, Qari, Shoukat H, Jackson, Eddie, Cong51, Mian-er, Masciotra, Silvina, Wei Luo, Kim, Caryn, Adams, Debra R, Monsour, Michael, Lipscomb, Jonathan, Johnson, Jeffrey A., Delinsky, David, Schinazi, Raymond F., Janssen, Robert, Folks, Thomas M., and Heneine, Walid
- Subjects
- *
ANTIRETROVIRAL agents , *HIV infections , *HIV , *MACAQUES - Abstract
Using a repeat-exposure macaque model, Walid Heneine and colleagues find that pre-exposure prophylaxis with combination antiretroviral drugs provides protection against rectal challenge with a SHIV virus. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
13. Absence of SHIV infection in gut and lymph node tissues in rhesus monkeys after repeated rectal challenges following HIV-1 DNA/MVA immunizations
- Author
-
Aidoo, Michael, Otten, Ronald A., Rodriguez, Vanessa, Sariol, Carlos A., Martinez, Melween, Kraiselburd, Edmundo, Robinson, Harriet, Folks, Thomas, Butera, Salvatore, and Ellenberger, Dennis
- Subjects
- *
MACAQUES , *LYMPH nodes , *VIRUS diseases , *VACCINATION - Abstract
Abstract: We reported previously the absence of systemic infection in a subset of macaques vaccinated with an HIV-1 DNA/MVA vaccine after 18 or more rectal challenges with low (physiologically relevant) doses of SHIV162P3. To further study the apparent protection, we looked for sequestered virus in gut tissues, lymph nodes, spleen, and testes obtained at necropsy using virus co-culture and nested PCR for SIV Gag, Pol and LTR. There was no evidence of sequestered virus in tissues obtained from the four protected macaques. In contrast, at least one tissue from each of 11 infected animals scored positive by one of these sensitive procedures. Activated PBMC from the protected macaques were not inherently resistant to in vitro infection by the challenge virus. These findings demonstrate that some vaccinated macaques appeared to be free from the challenge virus. Therefore, such T cell-based vaccines may provide some protection when challenge virus doses approach physiological equivalencies. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
14. Chemoprophylaxis with Tenofovir Disoproxil Fumarate Provided Partial Protection against Infection with Simian Human Immunodeficiency Virus in Macaques Given Multiple Virus Challenges.
- Author
-
Subbarao, Shambavi, Otten, Ronald A., Ramos, Artur, Kim, Caryn, Jackson, Eddie, Monsour, Michael, Adams, Debra R., Bashirian, Sheila, Johnson, Jeffrey, Soriano, Vincent, Rendon, Ana, Hudgens, Michael G., Butera, Salvatore, Janssen, Robert, Paxton, Lynn, Greenberg, Alan E., and Folks, Thomas M.
- Subjects
- *
CHEMOPREVENTION , *HIV infections , *DRUG efficacy , *RHESUS monkeys , *TISSUE culture , *PREVENTIVE medicine - Abstract
We examined the efficacy of tenofovir disoproxil fumarate (TDF) in blocking simian human immunodeficiency virus (SHIV) infection in Chinese rhesus macaques. Once weekly for 14 weeks or until a macaque became infected, 12 male macaques were inoculated intrarectally with amounts of SHIVSF162P3 (10 median tissue culture infective doses; 3.8×105 virus particles) that were ∼5-fold higher than the human immunodeficiency virus type 1 RNA levels noted in human semen during an acute infection. Of the 12 macaques, 4 received oral TDF daily, 4 received oral TDF once weekly, and 4 (control animals) received no TDF. The control animals became infected after receiving a median of 1.5 virus inoculations; macaques receiving TDF daily (1 macaque remained uninfected after 14 inoculations) and those receiving TDF weekly became infected after a median duration of 6.0 and 7.0 weeks, respectively. Although infection was delayed in treated macaques, compared with control macaques, the differences were not statistically significant (P = .315); however, the study was limited by the small numbers of animals evaluated and the variability in blood levels of TDF that resulted from oral dosing. These data demonstrate that treatment with oral TDF provided partial protection against SHIV infection but ultimately did not protect all TDF treated animals against multiple virus challenges. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
15. HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges
- Author
-
Ellenberger, Dennis, Otten, Ronald A., Li, Bin, Aidoo, Michael, Rodriguez, I. Vanessa, Sariol, Carlos A., Martinez, Melween, Monsour, Michael, Wyatt, Linda, Hudgens, Michael G., Kraiselburd, Edmundo, Moss, Bernard, Robinson, Harriet, Folks, Thomas, and Butera, Salvatore
- Subjects
- *
HIV infections , *DISEASES , *PREVENTIVE medicine , *NUCLEIC acids - Abstract
Abstract: Historically, HIV vaccines specifically designed to raise cellular immunity resulted in protection from disease progression but not infection when tested in monkeys challenged with a single high virus exposure. An alternative approach, more analogous to human sexual exposures, is to repetitively challenge immunized monkeys with a much lower dose of virus until systemic infection is documented. Using these conditions to mimic human sexual transmission, we found that a multi-protein DNA/MVA HIV-1 vaccine is indeed capable of protecting rhesus monkeys against systemic infection when repeatedly challenged with a highly heterologous immunodeficiency virus (SHIV). Furthermore, this repetitive challenge approach allowed us to calculate per-exposure probability of infection, an observed vaccine efficacy of 64%, and undertake a systematic analysis for correlates of protection based on exposures needed to achieve infection. Therefore, improved non-human primate models for vaccine efficacy can provide novel insight and perhaps renew expectations for positive outcomes of human HIV clinical trials. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
16. Repetitive exposures with simian/human immunodeficiency viruses: strategy to study HIV pre-clinical interventions in non-human primates.
- Author
-
Kim, Caryn N., Adams, Debra R., Bashirian, Sheila, Butera, Sal, Folks, Thomas M., and Otten, Ron A.
- Subjects
- *
HIV infections , *SIMIAN viruses , *AIDS , *PRIMATES , *HIV - Abstract
Background Non-human primate models for human immunodeficiency virus (HIV) infection represent a valuable pre-clinical tool to evaluate interventions (e.g., topical microbicides, vaccines, and chemoprophylaxis) designed to prevent transmission or slow disease progression after infection. Standard transmission models use a single-dose exposure with high, non-physiologic levels of virus to approach 100% infection rates of control animals. These single-exposure models do not represent the circumstances of mucosal HIV transmission in humans and may result in misleading data with regard to intervention efficacy. Therefore, we have developed a repetitive mucosal exposure model using doses of virus that better reflects human exposures. Methods The virus used for these evaluations was simian-human immunodeficiency virus [SHIVSF162P3 (R5-using, subtype B HIV-1 envelope)] and the virus dose used (approximately 105–106 viral particle equivalents or approximately 10 tissue culture infectious doses per exposure) approximates viral loads observed in the semen during acute HIV-1 infection. Using the repeated mucosal exposure approach, we have evaluated a candidate vaginal microbicide (cellulose acetate phthalate, CAP) given 15 minutes prior to each weekly virus exposure. Pig-tailed macaques were exposed weekly by vaginal inoculations with and without microbicide until systemic viral RNA was detected. Results Groups of naïve control monkeys were infected after an average of three to four exposures for the vaginal route of inoculation. Data from the first application of this monkey model to evaluate the topical microbicide CAP suggested that protection from SHIV infection was possible with three of four CAP-treated monkeys remaining uninfected after 12 exposures ( P = 0.015). CAP efficacy was markedly improved from 66% in a previous single-dose virus exposure study to 92% in this repeated exposure system. Conclusion Our experience with using repetitive virus exposures to study topical microbicides and the findings to date from this study provides a basis to refine monkey models to more closely resemble human exposure during HIV transmission. This model may be highly relevant to pre-clinical evaluation for a variety of therapeutic interventions which is discussed here. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
17. Emergence of unique primate T-lymphotropic viruses among central African bushmeat hunters.
- Author
-
Wolfe, Nathan D., Heneine, Walid, Carr, Jean K., Garcia, Albert D., Shanmugam, Vedapuri, Tamoufe, Ubald, Torimiro, Judith N., Prosser, A. Tassy, Lebreton, Matthew, Mpoudi-Ngole, Eitel, McCutchan, Francine E., Birx, Deborah L., Folks, Thomas M., Burke, Donald S., and Switzer, William M.
- Subjects
- *
HTLV , *MICROORGANISMS , *BLOOD , *MAMMALS , *DIAGNOSIS , *DISEASES - Abstract
The human T-lymphotropic viruses (HTLVs) types 1 and 2 originated independently and are related to distinct lineages of simian T-lymphotropic viruses (STLV-1 and STLV-2, respectively). These facts, along with the finding that HTLV-1 diversity appears to have resulted from multiple cross-species transmissions of STLV-1, suggest that contact between humans and infected nonhuman primates (NHP5) may result in HTLV emergence. We investigated the diversity of HTLV among central Africans reporting contact with NHP blood and body fluids through hunting, butchering, and keeping primate pets. We show that this population is infected with a wide variety of HTLVs, including two previously unknown retroviruses: HTLV-4 is a member of a phylogenetic lineage that is distinct from all known HTLV5 and STLVs; HTLV-3 falls within the phylogenetic diversity of STLV-3, a group not previously seen in humans. We also document human infection with multiple STLV-1-like viruses. These results demonstrate greater HTLV diversity than previously recognized and suggest that NHP exposure contributes to HTLV emergence. Our discovery of unique and divergent HTLVs has implications for HTLV diagnosis, blood screening, and potential disease development in infected persons. The findings also indicate that cross-species transmission is not the rate-limiting step in pandemic retrovirus emergence and suggest that it may be possible to predict and prevent disease emergence by surveillance of populations exposed to animal reservoirs and interventions to decrease risk factors, such as primate hunting. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
18. Multiple Vaginal Exposures to Low Doses of R5 Simian-Human Immunodeficiency Virus: Strategy to Study HIV Preclinical Interventions in Nonhuman Primates.
- Author
-
Otten, Ron A., Adams, Debra R., Kim, Caryn N., Jackson, Eddie, Pullium, Jennifer K., Lee, Kemba, Grohskopf, Lisa A., Monsour, Michael, Butera, Sal, and Folks, Thomas M.
- Subjects
- *
HIV , *HIV infections , *HIV infection transmission , *IMMUNODEFICIENCY , *PRIMATES , *LABORATORY monkeys - Abstract
A nonhuman-primate model of human immunodeficiency virus type 1 (HIV-1) infection that more closely emulates human heterosexual transmission by use of multiple exposures to low doses of virus is critical to better evaluate intervention strategies that include microbicides or vaccines. In this report, we describe such a system that uses female pig-tailed macaques exposed vaginally to a CCR5-using simian-human immuno-deficiency virus (SHIV162P3) at weekly intervals. Results of dose-titration experiments indicated that 3 once-weekly exposures to 10 tissue culture infectious doses of SHIV162P3 resulted in consistent transmission of virus and establishment of systemic infection. The efficacy of cellulose acetate phthalate (CAP) as a vaginal microbicide was evaluated by applying it to the vaginal vault of macaques (n = 4) 15 mm before each weekly exposure to SHIV162P3. One conclusion that can be drawn from the data derived from multiple exposures to virus is that CAP prevented infection in 12 of 13 possible chances for infection, over the course of 39 total exposures. Our findings provide a basis to refine monkey models for transmission of HIV-1, which may be relevant to preclinical evaluation for therapeutic interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
19. Recombinant Viruses and Early Global HIV-1 Epidemic.
- Author
-
Kalish, Marcia L., Robbins, Kenneth E., Pieniazek, Danuta, Schaefer, Amanda, Nzilambi, Nzila, Quinn, Thomas C., St. Louis, Michael E., Youngpairoj, Ae S., Phillips, Jonathan, Jaffe, Harold W., and Folks, Thomas M.
- Subjects
- *
RECOMBINANT viruses , *ENZYME-linked immunosorbent assay , *HIV , *EPIDEMICS , *HIV infections - Abstract
Central Africa was the epicenter of the HIV type 1 (HIV-1) pandemic. Understanding the early epidemic in the Democratic Republic of the Congo, formerly Zaire, could provide insight into how HIV evolved and assist vaccine design and intervention efforts. Using enzyme immunosorbent assays, we tested 3,988 serum samples collected in Kinshasa in the mid-1980s and confirmed seroreactivity by Western blot. Polymerase chain reaction of gag p17, env C2V3C3, and/or gp41; DNA sequencing; and genetic analyses were performed. Gene regions representing all the HIV-1 group M clades and unclassifiable sequences were found. From two or three short gene regions, 37% of the strains represented recombinant viruses, multiple infections, or both, which suggests that if whole genome sequences were available, most of these strains would have mosaic genomes. We propose that the HIV epidemic was well established in central Africa by the early 1980s and that some recombinant viruses most likely seeded the early global epidemic. [ABSTRACT FROM AUTHOR]
- Published
- 2004
20. Window-period human immunodeficiency virus transmission to two recipients by an adolescent blood donor.
- Author
-
Phelps, Ruby, Robbins, Kenneth, Liberti, Thomas, Machuca, Ana, Leparc, German, Chamberland, Mary, Kalish, Marcia, Hewlett, Indira, Folks, Thomas, Lee, Lisa M., and McKenna, Matthew
- Subjects
- *
BLOOD transfusion , *HIV infection transmission , *BLOOD transfusion reaction , *HIV infections , *ORGAN donation , *BLOOD donors - Abstract
Pooled NAT and donor screening have reduced the diagnostic window period for HIV in the blood donor population to approximately 10 to 15 days. This report describes two cases of transfusion-acquired HIV infection and verification of transmission from the donor to the recipients, and attempts to identify how the 18-year-old donor acquired her infection. After a repeat donor had a positive HIV test result, two recipients of the donor's previous donation were identified and tested. The donor and recipients were interviewed and blood samples were obtained for HIV DNA sequencing and phylogenetic analysis. The two recipients had positive HIV test results. Phylogenetic analysis showed a high genetic similarity among the viruses (bootstrap 100%), consistent with transmission from the donor to the recipients. Four of five men with whom the donor had sexual contact during the critical time period when infection most likely occurred were located and tested; results were negative for HIV. Pooled NAT of blood donations has not eliminated the window period for HIV identification during seroconversion. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
21. Frequent Simian Foamy Virus Infection in Persons Occupationally Exposed to Nonhuman Primates.
- Author
-
Switzer, William M., Bhullar, Vinod, Shanmugam, Vedapuri, Mian-er Cong, Vedapuri, Parekh, Bharat, Lerche, Nicholas W., Yee, JoAnn L., Ely, John J., Boneva, Roumiana, Chapman, Louisa E., Folks, Thomas M., and Heneine, Walid
- Subjects
- *
SIMIAN viruses , *AIDS , *PUBLIC health , *OCCUPATIONAL diseases , *VIRAL antibodies , *VIRUSES - Abstract
The recognition that AIDS originated as a zoonosis heightens public health concerns associated with human infection by simian retroviruses endemic in nonhuman primates (NHPs). These retroviruses include simian immunodeficiency virus (SIV), simian T-cell lymphotropic virus (STLV), simian type D retrovirus (SRV), and simian foamy virus (SFV). Although occasional infection with SIV, SRV, or SFV in persons occupationally exposed to NHPs has been reported, the characteristics and significance of these zoonotic infections are not fully defined. Surveillance for simian retroviruses at three research centers and two zoos identified no SIV, SRV, or STLV infection in 187 participants. However, 10 of 187 persons (5.3%) tested positive for SFV antibodies by Western blot (WB) analysis. Eight of the 10 were males, and 3 of the 10 worked at zoos. SFV integrase gene (int) and gag sequences were PCR amplified from the peripheral blood lymphocytes available from 9 of the 10 persons. Phylogenetic analysis showed SFV infection originating from chimpanzees (n = 8) and baboons (n = 1). SFV seropositivity for periods of 8 to 26 years (median, 22 years) was documented for six workers for whom archived serum samples were available, demonstrating long-standing SFV infection. All 10 persons reported general good health, and secondary transmission of SFV was not observed in three wives available for WB and PCR testing. Additional phylogenetic analysis of int and gag sequences provided the first direct evidence identifying the source chimpanzees of the SFV infection in two workers. This study documents more frequent infection with SFV than with other simian retroviruses in persons working with NHPs and provides important information on the natural history and species origin of these infections. Our data highlight the importance of studies to better define the public health implications of zoonotic SFV infections. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
22. Optimization of a multi-gene HIV-1 recombinant subtype CRF02_AG DNA vaccine for expression of multiple immunogenic forms
- Author
-
Ellenberger, Dennis, Li, Bin, Smith, James, Yi, Hong, Folks, Thomas, Robinson, Harriet, and Butera, Salvatore
- Subjects
- *
HIV , *DNA vaccines , *MICROBIAL mutation - Abstract
We developed an AIDS vaccine for Western and West-Central Africa based on a DNA plasmid vector expressing HIV-1 recombinant subtype CRF02_AG gag, pol, and env genes. To optimize the production of noninfectious HIV-like particles (VLPs) and potentially improve the effectiveness of the vaccine, we generated four potential vaccine constructs: the parental (IC2) and three modifications (IC25, IC48, and IC90) containing mutations within the HIV protease. While the parental construct IC2 expressed aggregates of Gag proteins, the IC25 construct resulted in the production of immature VLPs (the core comprises unprocessed Pr55Gag). The remaining two constructs (IC48 and IC90) produced mature VLPs (the core comprises processed capsid p24) in addition to immature VLPs and aggregates of Gag proteins. VLPs incorporated significant levels of mature gp120 envelope glycoprotein. Importantly, the mature VLPs were fusion competent and entered coreceptor-specific target cells. The production of multiple antigenic forms, including fusion-competent VLPs, by candidate DNA vaccine constructs may provide immunologic advantages for induction of protective cellular and humoral responses against HIV-1 proteins. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
23. Generation of a Consensus Sequence from Prevalent and Incident HIV-1 Infections in West Africa to Guide AIDS Vaccine Development
- Author
-
Ellenberger, Dennis L., Li, Bin, Lupo, L. Davis, Owen, S. Michele, Nkengasong, John, Kadio-Morokro, Madeleine Sassan, Smith, James, Robinson, Harriet, Ackers, Marta, Greenberg, Alan, Folks, Thomas, and Butera, Salvatore
- Subjects
- *
HIV , *VACCINES - Abstract
We considered several key issues regarding the development of a DNA-based human immunodeficiency virus type 1 (HIV-1) vaccine: (1) should the candidate vaccine construct be derived from incident or prevalent HIV-1 strains; and (2) should circulating plasma virus, archived HIV-1 provirus recovered from peripheral blood mononuclear cells, or both be included? To address these questions, we collected circulating HIV-1 strains from infected individuals residing in Abidjan, Coˆte d'Ivoire. From a panel of 23 strains, 22 were HIV-1 subtype A in gag, 19 of which phylogenetically clustered with the recombinant HIV-1, CRF02-AG strains from West Africa. The mosaic genome of CRF02-AG was confirmed by sequencing the protease gene. A consensus gag p24 protein sequence was generated and 147 of 148 codons were identical to CRF02-AG (IbNG). Regardless of the sequence origin (RNA, provirus, incident, or prevalent), the gag p24 consensus sequences were highly representative of these distinct virologic compartments. These data suggest that the consensus sequence generated from incident and prevalent infections may provide an appropriate sequence for a DNA vaccine and is largely representative of the major circulating viral strain. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
24. Chronic immune stimulation accelerates SIV-induced disease progression.
- Author
-
Villinger, François, Rowe, Thomas, Parekh, Bharat S., Green, Timothy A., Mayne, Ann E., Grimm, Bennett, McClure, Harold M., Lackner, Andrew A., Dailey, Peter J., Ansari, Aftab A., and Folks, Thomas M.
- Subjects
- *
IMMUNE system , *LENTIVIRUS diseases - Abstract
The contribution of chronic immune stimulation on the progression of lentivirus-induced disease was evaluated in the SIVmac251 macaque model of AIDS. Following SIV inoculation, seroconversion and control of the acute viral replication phase, repeated immune stimulations with tetanus toxoid (TT), keyhole limpet hemocyanin (KLH) and allogeneic peripheral blood mononuclear cells (PBMC) were initiated in four monkeys. These animals showed a significant shortening of survival when compared with eight non-immune-stimulated control animals inoculated with the same route, dose and stock of SIVmac251 (median survival 9.5 months versus 17 months. P = 0.010). In addition, when the comparision was extended to another 22 control animals of different origin but inoculated by the same route with similar doses and stocks of SIVmac251, the difference in survival was still significant (9.5 versus 18 months, P = 0.003). This accelerated progression of symptomatic disease was not accompanied with significant increases in plasma viral loads, but suboptimal antibody responses to the immunizing antigens were noted, correlating with the length of survival. These findings may have implications for HIV-infected humans suffering from chronic infectious diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
25. Pig-tailed Macaques Infected with Human Immunodeficiency Virus (HIV) Type 2 [subGB122] of Simian/HIV [sub89.6p] Express Virus in Semen during Primary Infection: New Model for Genital Tract Shedding and Transmission.
- Author
-
Pullium, Jennifer K., Adams, Debra R., Kim, Caryn N., Folks, Thomas M., Butera, Sal, Otten, Ron A., Jackson, Eddie, Smith, Dawn K., Janssen, Robert, and Gould, Kenneth
- Subjects
- *
MALE reproductive organs , *HIV infections - Abstract
Provides information on a study which evaluated male genital tract shedding to characterize HIV expression in semen during primary infection. Methods; Virologic characterization after simian/HIV infection; Virus-specific antibody responses and lymphocyte fluctuations during primary infection.
- Published
- 2001
- Full Text
- View/download PDF
26. Evidence of Porcine Endogenous Retroviruses in Porcine Factor VIII and Evaluation of Transmission to Recipients with Hemophilia.
- Author
-
Heneine, Walid, Switzer, William M., Shanmugam, Vedapuri, Rosales, Guillermo Vazquez, Matthews, Aprille, Sandstrom, Paul, Folks, Thomas M., Soucie, J. Michael, and Evatt, Bruce L.
- Subjects
- *
RETROVIRUSES , *BLOOD plasma , *REVERSE transcriptase - Abstract
Studies the presence of porcine endogenous retrovirus (PERV) in plasma samples of pigs and in clinical lots of unheated porcine clotting factor VIII concentrate (Hyate:C). Background of the study; Reverse-transcriptase polymerase reaction testing of PERV RNA in pig serum/plasma samples and Hyate:C; RT activity screening in pig serum/plasma samples and Hyate:C products; PERV envelope subtype analysis; Results; Discussion.
- Published
- 2001
- Full Text
- View/download PDF
27. Lack of evidence of endogenous avian leukosis virus and endogenous avian retrovirus transmission to measles, mumps, and rubella vaccine recipients.
- Author
-
Hussain, Althaf I., Shanmugam, Vedapuri, Switzer, William M., Tsang, Shirley X., Helfand, Rita, Bellini, William J., Folks, Thomas M., Heneine, Walid, Fadly, Aly, Thea, Donald, Hussain, A I, Shanmugam, V, Switzer, W M, Tsang, S X, Fadly, A, Thea, D, Helfand, R, Bellini, W J, Folks, T M, and Heneine, W
- Subjects
- *
VACCINATION , *AVIAN leukosis , *RETROVIRUS diseases , *MEASLES vaccines , *MUMPS vaccines , *HEALTH - Abstract
The identification of endogenous avian leukosis virus (ALV) and endogenous avian retrovirus (EAV) in chick cell-derived measles and mumps vaccines in current use has raised concern about transmission of these retroviruses to vaccine recipients. We used serologic and molecular methods to analyze specimens from 206 recipients of measles, mumps, and rubella (MMR) vaccine for evidence of infection with ALV and EAV. A Western blot assay for detecting antibodies to endogenous ALV was developed and validated. All serum samples were negative for antibodies to endogenous ALV by Western blot analysis. Peripheral blood lymphocyte samples from 100 vaccinees were further tested by polymerase chain reaction for both ALV and EAV proviral sequences; all were negative. Matching serum samples were tested by reverse transcriptase polymerase chain reaction for ALV and EAV RNA, and all 100 samples were negative, providing no evidence of viremia. These findings do not indicate the presence of either ALV or EAV infection in MMR vaccine recipients and provide support for current immunization policies. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
28. Failure of Routine HIV-1 Tests in a Case Involving Transmission With Preseroconversion Blood Components During the Infections Window Period.
- Author
-
Ai Ee Ling, Robbins, Kenneth E., Brown, Teresa M., Dunmire, Valerie, Su Yun Se Thoe, Sin-Yew Wong, Yee Sin Leo, Teo, Diana, Gallarda, James, Phelps, Bruce, Chamberland, Mary E., Busch, Michael P., Folks, Thomas M., and Kalish, Marcia L.
- Subjects
- *
BLOOD transfusion , *DIAGNOSIS of HIV infections , *BLOOD testing , *BLOOD donors , *PERIODIC health examinations - Abstract
Presents a study designed to determine HIV-1 genetic linkage between virus in 2 HIV-infected recipients of blood components and virus in the donor, who was HIV antigen and antibody negative at the time of donation. Methods; Results; Conclusion that United States HIV nucleic acid amplification (NAT) may not be sufficiently sensitive to detect all infectious window-period donations.
- Published
- 2000
- Full Text
- View/download PDF
29. No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts.
- Author
-
Heneine, Walid, Tibell, Annika, Swtizer, William M., Sandstrom, Paul, Rosales, Guillermo Vasquez, Matthews, Aprille, Kosgren, Olle, Chapman, Louisa E., Folks, Thomas M., and Groth, Carl G.
- Subjects
- *
XENOGRAFTS , *RETROVIRUS diseases , *COMPLICATIONS from organ transplantation , *INFECTIOUS disease transmission - Abstract
Presents research which studied whether porcine xenografts can lead to porcine endogenous retrovirus (PERV) infection of recipients. PERV carried in the pig germline; Exposure of patients to the virus; Methods; Findings; Absence of PERV infections in these patients; Minimum standard for post-transplant surveillance of patients given porcine xenografts.
- Published
- 1998
- Full Text
- View/download PDF
30. Assessment of a Retrovirus Sequence and Other Possible Risk Factors for the Chronic Fatigue Syndrome in Adults.
- Author
-
Kahn, Ali S., Heneine, Walid M., Chapman, Louisa E., Gray Jr., Howard E., Woods, Toni C., Folks, Thomas M., and Schonberger, Lawrence B.
- Subjects
- *
CHRONIC fatigue syndrome , *HTLV , *RETROVIRUS genetics - Abstract
Presents a study that investigated the prevalence of human T-lymphotropic virus type II (HTLV-II) gag gene retrovirus markers in persons with chronic fatigue syndrome (CFS) in the U.S. Identification of risk factors associated with CFS; Measurement of the prevalence of potential risk factors before illness onset for CFS; Examination of the sequence of the HTLV-II gag gene.
- Published
- 1993
- Full Text
- View/download PDF
31. A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection.
- Author
-
Buchwald, Dedra, Cheney, Paul R., Peterson, Daniel L., Henry, Berch, Wormsley, Susan B., Geiger, Ann, Ablashi, Dharam V., Salahuddin, S. Zaki, Saxinger, Carl, Biddle, Royce, Kikinis, Ron, Jolesz, Ferene A., Folks, Thomas, Balachandran, N., Peter, James B., Gallo, Robert C., Komaroff, Anthony L., Buchwald, D, Cheney, P R, and Peterson, D L
- Subjects
- *
CHRONIC diseases , *NEUROLOGIC manifestations of general diseases , *IMMUNOLOGIC diseases - Abstract
Objective: To conduct neurologic, immunologic, and virologic studies in patients with a chronic debilitating illness of acute onset.Design: Cohort study with comparison to matched, healthy control subjects.Patients: We studied 259 patients who sought care in one medical practice; 29% of the patients were regularly bedridden or shut-in.Main Outcome Measures: Detailed medical history, physical examination, conventional hematologic and chemistry testing, magnetic resonance imaging (MRI) studies, lymphocyte phenotyping studies, and assays for active infection of patients' lymphocytes with human herpesvirus type 6 (HHV-6).Main Results: Patients had a higher mean (+/- SD) CD4/CD8 T-cell ratio than matched healthy controls (3.16 +/- 1.5 compared with 2.3 +/- 1.0, respectively; P less than 0.003). Magnetic resonance scans of the brain showed punctate, subcortical areas of high signal intensity consistent with edema or demyelination in 78% of patients (95% CI, 72% to 86%) and in 21% of controls (CI, 11% to 36%) (P less than 10(-9)). Primary cell culture of lymphocytes showed active replication of HHV-6 in 79 of 113 patients (70%; CI, 61% to 78%) and in 8 of 40 controls (20%; CI, 9% to 36%) (P less than 10(-8], a finding confirmed by assays using monoclonal antibodies specific for HHV-6 proteins and by polymerase chain reaction assays specific for HHV-6 DNA.Conclusions: Neurologic symptoms, MRI findings, and lymphocyte phenotyping studies suggest that the patients may have been experiencing a chronic, immunologically mediated inflammatory process of the central nervous system. The active replication of HHV-6 most likely represents reactivation of latent infection, perhaps due to immunologic dysfunction. Our study did not directly address whether HHV-6, a lymphotropic and gliotropic virus, plays a role in producing the symptoms or the immunologic and neurologic dysfunction seen in this illness. Whether the findings in our patients, who came from a relatively small geographic area, will be generalizable to other patients with a similar syndrome remains to be seen. [ABSTRACT FROM AUTHOR]- Published
- 1992
- Full Text
- View/download PDF
32. Risk of nosocomial infection with human T-cell lymphotropic virus type III/lymphadenopathy-associated virus in a large cohort of intensively exposed health care workers.
- Author
-
Henderson, David K., Saah, Alfred J., Zak, Barbara J., Kaslow, Richard A., Lane, H. Clifford, Folks, Thomas, Blackwelder, William C., Schmitt, James, LaCamera, Deborah J., Masur, Henry, Fauci, Anthony S., Henderson, D K, Saah, A J, Zak, B J, Kaslow, R A, Lane, H C, Folks, T, Blackwelder, W C, Schmitt, J, and LaCamera, D J
- Subjects
- *
HIV , *MEDICAL personnel , *INFECTIOUS disease transmission , *DISEASES - Abstract
To assess the risk of nosocomial transmission of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV), we prospectively evaluated a cohort of 531 health care workers. One hundred fifty of these employees reported percutaneous or mucous membrane exposures to blood or body fluids from a patient with the acquired immunodeficiency syndrome (AIDS) during the treatment of 238 such patients since 1981. None of these 150 employees had serologic evidence of HTLV-III/LAV infection on follow-up from 6 to 46 months after exposure. Of the 150, 46 were studied immunologically and 29 had lymphocytes cultured for HTLV-III/LAV. Results of all studies were normal. Of the 531 employees, 3 (0.56%) had serologic evidence of HTLV-III/LAV infection. All were seropositive at the time of study entry; none reported adverse nosocomial exposures. All acknowledged membership in one or more established risk groups for AIDS. This study provides strong evidence that the risk of nosocomial transmission of HTLV-III/LAV is extremely low. [ABSTRACT FROM AUTHOR]
- Published
- 1986
- Full Text
- View/download PDF
33. Central African hunters exposed to simian immunodeficiency virus.
- Author
-
Kalish, Marcia L., Wolfe, Nathan D., Ndongmo, Clement B., McNicholl, Janet, Robbins, Kenneth E., Aidoo, Michael, Fonjungo, Peter N., Alemnji, George, Zeh, Clement, Djoko, Cyrille F., Mpoudi-Ngole, Eitel, Burke, Donald S., and Folks, Thomas M.
- Subjects
- *
EPIDEMIOLOGICAL research , *SIMIAN viruses , *HIV - Abstract
HIV-seronegative Cameroonians with exposure to nonhuman primates were tested for simian immunodeficiency virus (SIV) infection. Seroreactivity was correlated with exposure risk (p<0.001). One person had strong humoral and weak cellular immune reactivity to SIVcol peptides. Humans are exposed to and possibly infected with SIV, which has major public health implications. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
34. Divergent HIV and Simian Virus Surveillance, Zaire.
- Author
-
Schaefer, Amanda, Robbins, Kenneth E., Nzilambi, Eugene Nzila, St. Louis, Michael E., Quinn, Thomas C., Folks, Thomas M., Kalish, Marcia L., and Pieniazek, Danuta
- Subjects
- *
HIV infections , *SIMIAN viruses , *WESTERN immunoblotting , *ENZYME-linked immunosorbent assay - Abstract
Recent HIV infection or divergent HIV or simian immunodeficiency virus (SIV) strains may be responsible for Western blot-indeterminate results on 70 serum samples from Zairian hospital employees that were reactive in an enzyme immunoassay. Using universal polymerase chain reaction HIV-1, HIV-2, and SIV primers, we detected 1 (1.4%) HIV-1 sequence. Except for 1 sample, no molecular evidence for unusual HIV- or SIV-like strains in this sampling was found. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
35. Simian foamy virus infection among zoo keepers.
- Author
-
Sandstrom, Paul A., Phan, Kim Oanh, Switzer, William M., Fredeking, Terry, Chapman, Louisa, Heneine, Walid, and Folks, Thomas M.
- Subjects
- *
ZOO employees , *SIMIAN viruses , *ZOONOSES , *RETROVIRUS diseases , *HEALTH , *INFECTIOUS disease transmission , *PREVENTION - Abstract
We investigated 322 North American zoo workers in an anonymous serosurvey for antibodies to simian foamy viruses to establish the potential risk of zoonotic transmission by these retroviruses. 4 of 133 (3%) individuals who worked specifically with mammals including primates were seropositive, primarily with chimp-like viruses, indicating the importance of work practices to reduce exposure to these agents. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
36. Complete Protection from Repeated Vaginal Simian-Human Immunodeficiency Virus Exposures in Macaques by a Topical Gel Containing Tenofovir Alone or with Emtricitabine.
- Author
-
Parikh, Urvi M., Dobard, Charles, Sharma, Sunita, Cong, Mian-Er, Hongwei Jia, Martin, Amy, Chou-Pong Pau, Hanson, Debra L., Guenthner, Patricia, Smith, James, Kersh, Ellen, Garcia-Lerma, J. Gerardo, Novembre, Francis J., Otten, Ron, Folks, Thomas, and Heneine, Walid
- Subjects
- *
HIV prevention , *ANTISEPTICS , *ANIMAL models in research , *MACAQUES , *T cells , *THERAPEUTICS - Abstract
New-generation gels that deliver potent antiretroviral drugs against human immunodeficiency virus type 1 have renewed hopes for topical prophylaxis as a prevention strategy. Previous preclinical research with monkey models suggested that high concentrations and drug combinations are needed for high efficacy. We evaluated two long-acting reverse transcriptase inhibitors, tenofovir (TFV) and emtricitabine (FTC), by using a twice-weekly repeat challenge macaque model and showed that a preexposure vaginal application of gel with 1% TFV alone or in combination with 5% FTC fully protected macaques from a total of 20 exposures to simian-human immunodeficiency virus SF162p3. FTC and TFV were detected in plasma 30 min after vaginal application, suggesting rapid absorption. FTC was detected more frequently than TFV and showed higher levels, reflecting the fivefold-higher concentration of this drug than of TFV. Two of 12 repeatedly exposed but protected macaques showed limited T-cell priming, which did not induce resistance to infection when macaques were rechallenged. Thus, single drugs with durable antiviral activity can provide highly effective topical prophylaxis and overcome the need for noncoital use or for drug combinations which are more complex and costly to formulate and approve. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
37. Ancient Origin and Molecular Features of the Novel Human T-Lymphotropic Virus Type 3 Revealed by Complete Genome Analysis.
- Author
-
Switzer, William M., Qari, Shoukat H., Wolfe, Nathan D., Burke, Donald S., Folks, Thomas M., and Heneine, Walid
- Subjects
- *
HIV , *GENETICS , *GENOMES , *LYMPHOCYTES , *PHYLOGENY , *VIRUSES - Abstract
Human T-lymphotropic virus type 3 (HTLV-3) is a new virus recently identified in two primate hunters in Central Africa. Limited sequence analysis shows that HTLV-3 is distinct from HTLV-1 and HTLV-2 but is genetically similar to simian T-lymphotropic virus type 3 (STLV-3). We report here the first complete HTLV-3 sequence obtained by PCR-based genome walking using uncultured peripheral blood lymphocytes from an HTLV-3-infected person. The HTLV-3(2026ND) genome is 8,917 bp long and is genetically equidistant from HTLV-1 and HTLV-2, sharing about 62% identity. Phylogenetic analysis of all gene regions confirms this relationship and shows that HTLV-3 falls within the diversity of STLV-3, suggesting a primate origin. However, HTLV-3(2026ND) is unique, sharing only 87% to 92% sequence identity with STLV-3. SimPlot and phylogenetic analysis did not reveal any evidence of genetic recombination with either HTLV-1, HTLV-2, or STLV-3. Molecular dating estimates that the ancestor of HTLV-3 is as old as HTLV-1 and HTLV-2, with an inferred divergence time of 36,087 to 54,067 years ago. HTLV-3 has a prototypic genomic structure, with all enzymatic, regulatory, and structural proteins preserved. Like STLV-3, HTLV-3 is missing a third 21-bp transcription element found in the long terminal repeats of HTLV-1 and HTLV-2 but instead contains a unique activator protein-1 transcription factor upstream of the 21-bp repeat elements. A PDZ motif, like that in HTLV-1, which is important for cellular signal transduction and transformation, is present in the C terminus of the HTLV-3 Tax protein. A basic leucine zipper region located in the antisense strand of HTLV-1, believed to play a role in viral replication and oncogenesis, was also found in the complementary strand of HTLV-3. The ancient origin of HTLV-3, the broad distribution of STLV-3 in Africa, and the propensity of STLVs to cross species into humans all suggest that HTLV-3 may be prevalent and support the need for expanded surveillance for this virus. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
38. Infection of a Laboratory Worker with Simian Immunodeficiency Virus.
- Author
-
Khabbaz, Rima F., Heneine, Walid, George, J. Richard, Parekh, Bharat, Rowe, Thomas, Woods, Toni, Switzer, William M., McClure, Harold M., Murphey-Corb, Michael, and Folks, Thomas M.
- Subjects
- *
SIMIAN viruses , *LABORATORY infections , *IMMUNODEFICIENCY , *LENTIVIRUSES , *HIV , *AIDS , *AIDS vaccines , *MEDICAL records , *HIV infections - Abstract
The article offers information on a laboratory worker with simian immunodeficiency virus (SIV) infection and a study done to investigate the SIV infection in humans. It reports that SIVs are primate lentiviruses that are biologically related to human immunodeficiency viruses (HIVs), and mentions their use in studying the pathogenesis of AIDS and developing an HIV vaccine. It states the development of antibodies that cross-reactive to HIV-2 and SIV in a laboratory worker, after percutaneous exposure to blood, and discusses the studies done on laboratory researchers for HIV and SIV infections. It also discusses the methodology used in the study and presents the medical history of the worker. Also presented are the study's results along with a discussion on SIV infections in humans.
- Published
- 1994
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.